Market Overview:
The global preventive asthma drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of asthma, rising awareness about preventive therapies for asthma, and technological advancements in the field of preventive asthma drugs. The global preventive asthma drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into somatostatin analogs, targeted therapy, and chemotherapy. Of these segments, somatostatin analogs are expected to account for a major share in terms of revenue in 2018 owing to their high efficacy and safety profile as compared to other types of drugs used for prevention purposes. On the basis of application, hospitals are expected to account for a major share in terms of revenue in 2018 owing to their large patient population base suffering from various respiratory disorders such as asthma.
Product Definition:
A preventive asthma drug is a medication that is taken on a regular basis to help prevent asthma attacks. These drugs are often used in combination with other medications, such as rescue inhalers, to help control asthma symptoms. Preventive asthma drugs can be oral or inhaled medications and vary in their level of effectiveness. The importance of using these drugs regularly cannot be overstated; they can help reduce the number and severity of asthma attacks, making it easier for people to live normal lives.
Somatostatin Analogs:
Somatostatin Analogs, it's usage.
The Somatostatin Analogs (SSAs) are a class of drug that enhances the inhibitory control over the release of somatostatin from the brain to gastrointestinal tract. SSAs’s ability to reduce gastrointestinal activity by inhibiting peptide YY (PYY) is one of its key attributes.
Targeted Therapy:
Targeted therapy is a type of medication used to treat asthma. It's main aim is to reduce the inflammation and irritation of the airways by reducing the amount of histamine and leukotrienes released by cells in response to normally harmless substances that trigger asthma symptoms. The most common types of targeted therapies are inhaled corticosteroids, leukotriene receptor antagonists, mast cell stabilizers (MCS), and long-acting beta-agonists.
Application Insights:
On the basis of application, the global preventive asthma drug market is segmented into hospital, clinics and oncology centers. The hospital segment dominated the overall market in terms of revenue share in 2017. This can be attributed to a large patient base and high prevalence of chronic diseases such as asthma and COPD that require long-term care. In addition, hospitals are considered to be one of the highest priority areas for preventative medication due to rising awareness among patients regarding their health conditions along with continuous monitoring by healthcare professionals.
The clinics & oncology centers segment is expected to grow at a lucrative rate over the forecast period owing to increasing demand for effective treatment options without relapses or remissions coupled with an increase in cancer cases globally over recent years.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to favorable reimbursement policies, increasing prevalence of asthma, and availability of effective preventive drugs. In addition, rising awareness about chronic respiratory diseases among people is also one of the major factors responsible for maintaining this dominance.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to various initiatives taken by governments and private organizations for raising public awareness regarding preventive treatment for asthma attacks & prevention as well as control of COPD. For instance, in India; Asthma Control Program (ACP) was launched by WHO/PAHO and Indian Council Of Medical Research (ICMR).
Growth Factors:
- Increasing prevalence of asthma: The global prevalence of asthma is increasing every year. This will lead to an increase in the demand for preventive asthma drugs.
- Growing awareness about preventive measures: There is a growing awareness among people about the importance of taking preventive measures against asthma attacks. This will lead to an increase in the demand for preventive asthma drugs.
- Technological advancements: The development of new and innovative technologies is helping researchers develop better and more effective preventive asthma drugs. This will lead to an increase in the demand for such drugs in the future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Preventive Asthma Drug Market Research Report
By Type
Somatostatin Analogs, Targeted Therapy, Chemotherapy
By Application
Hospital, Clinics, Oncology Centres
By Companies
Xiaflex, Novartis AG, Roche, Molecular Insight Pharmaceuticals, Callisto Pharmaceuticals, Xiaflex
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
163
Number of Tables & Figures
115
Customization Available
Yes, the report can be customized as per your need.
Global Preventive Asthma Drug Market Report Segments:
The global Preventive Asthma Drug market is segmented on the basis of:
Types
Somatostatin Analogs, Targeted Therapy, Chemotherapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinics, Oncology Centres
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Xiaflex
- Novartis AG
- Roche
- Molecular Insight Pharmaceuticals
- Callisto Pharmaceuticals
- Xiaflex
Highlights of The Preventive Asthma Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Somatostatin Analogs
- Targeted Therapy
- Chemotherapy
- By Application:
- Hospital
- Clinics
- Oncology Centres
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Preventive Asthma Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A preventive asthma drug is a medication that helps to prevent asthma attacks. Preventive asthma drugs can be taken before you experience symptoms of an attack, or they can be taken regularly to help keep your airways open and reduce the chance of having an attack.
Some of the key players operating in the preventive asthma drug market are Xiaflex, Novartis AG, Roche, Molecular Insight Pharmaceuticals, Callisto Pharmaceuticals, Xiaflex.
The preventive asthma drug market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Preventive Asthma Drug Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Preventive Asthma Drug Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Preventive Asthma Drug Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Preventive Asthma Drug Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Preventive Asthma Drug Market Size & Forecast, 2018-2028 4.5.1 Preventive Asthma Drug Market Size and Y-o-Y Growth 4.5.2 Preventive Asthma Drug Market Absolute $ Opportunity
Chapter 5 Global Preventive Asthma Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Preventive Asthma Drug Market Size Forecast by Type
5.2.1 Somatostatin Analogs
5.2.2 Targeted Therapy
5.2.3 Chemotherapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Preventive Asthma Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Preventive Asthma Drug Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinics
6.2.3 Oncology Centres
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Preventive Asthma Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Preventive Asthma Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Preventive Asthma Drug Analysis and Forecast
9.1 Introduction
9.2 North America Preventive Asthma Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Preventive Asthma Drug Market Size Forecast by Type
9.6.1 Somatostatin Analogs
9.6.2 Targeted Therapy
9.6.3 Chemotherapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Preventive Asthma Drug Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinics
9.10.3 Oncology Centres
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Preventive Asthma Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Preventive Asthma Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Preventive Asthma Drug Market Size Forecast by Type
10.6.1 Somatostatin Analogs
10.6.2 Targeted Therapy
10.6.3 Chemotherapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Preventive Asthma Drug Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinics
10.10.3 Oncology Centres
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Preventive Asthma Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Preventive Asthma Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Preventive Asthma Drug Market Size Forecast by Type
11.6.1 Somatostatin Analogs
11.6.2 Targeted Therapy
11.6.3 Chemotherapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Preventive Asthma Drug Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinics
11.10.3 Oncology Centres
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Preventive Asthma Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Preventive Asthma Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Preventive Asthma Drug Market Size Forecast by Type
12.6.1 Somatostatin Analogs
12.6.2 Targeted Therapy
12.6.3 Chemotherapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Preventive Asthma Drug Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinics
12.10.3 Oncology Centres
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Preventive Asthma Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Preventive Asthma Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Preventive Asthma Drug Market Size Forecast by Type
13.6.1 Somatostatin Analogs
13.6.2 Targeted Therapy
13.6.3 Chemotherapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Preventive Asthma Drug Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinics
13.10.3 Oncology Centres
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Preventive Asthma Drug Market: Competitive Dashboard
14.2 Global Preventive Asthma Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Xiaflex
14.3.2 Novartis AG
14.3.3 Roche
14.3.4 Molecular Insight Pharmaceuticals
14.3.5 Callisto Pharmaceuticals
14.3.6 Xiaflex